Finance

Lists
Outlook: 62.2% bullish·0.0% bearish
Go to analysis
GILD:NASDAQ
Gilead Sciences, Inc
$153.07
-2.00%
(-3.12) 1D
$154.55
+0.97% (+1.48)
Pre-market
Closed: Oct 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GILD...
Open
$155.38
High
$157.24
Low
$152.92
Mkt. cap
189.80B
Avg. vol.
5.89M
Volume
2.61K
Dividend
2.14%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$160.51
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
Open
$155.38
High
$157.24
Low
$152.92
Mkt. cap
189.80B
Avg. vol.
5.89M
Volume
2.61K
Dividend
2.14%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$160.51
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
Analyst ratings
Based on 21 analysts giving stock ratings to GILD in the past 3 months
Strong buy
Buy
17
Hold
4
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for GILD in the last 3 months.
Highest
Current $153.07
$177.00 (+15.63%)
Average
$160.00 (+4.53%)
Lowest
$126.00 (-17.68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daina Graybosch
Leerink Partners
Hold
Reiterated
$129.00
-15.7%
10/15/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$165.00
+7.8%
10/14/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$174.00
+13.7%
10/12/2026
Geoff Meacham
Citi
Buy
Maintained
$165.00
+7.8%
10/12/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$168.00
+9.8%
10/12/2026
Michael Yee
UBS
Buy
Maintained
$175.00
+14.3%
10/09/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$126.00
-17.7%
10/08/2026
Louise Chen
Scotiabank
Buy
Reiterated
$177.00
+15.6%
10/08/2026
Gregory Renza
Truist Financial
Buy
Maintained
$158.00
+3.2%
10/07/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$163.00
+6.5%
10/07/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$170.00
+11.1%
10/07/2026
Morten Herholdt
HSBC
Buy
Maintained
$175.00
+14.3%
09/10/2026
Courtney Breen
Bernstein
Buy
Maintained
$160.00
+4.5%
09/07/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$170.00
+11.1%
08/31/2026
Emily Field
Barclays
Hold
Maintained
$145.00
-5.3%
08/13/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$165.00
+7.8%
08/06/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
08/05/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$155.00
+1.3%
08/04/2026
Joseph Stringer
Needham
Buy
Reiterated
$170.00
+11.1%
08/05/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$160.00
+4.5%
08/04/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$130.00
-15.1%
08/03/2026
Akash Tewari
Jefferies
Buy
Maintained
$180.00
+17.6%
05/22/2026
Unknown Analyst
Argus Research
Buy
Reiterated
$165.00
+7.8%
05/15/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$165.00
+7.8%
05/13/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
$145.00
-5.3%
02/11/2026
Next call in 9 days
Thu, Oct 29, 10:30 PM
Fiscal period
Q3 2026
- / $2.20
Revenue / Est. (USD)
- / 7.79B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.77B
7.92B
6.96B
7.80B
Cost of goods sold
1.57B
1.62B
1.44B
1.58B
Cost of revenue
1.57B
1.62B
1.44B
1.58B
Research and development expenses
1.33B
1.57B
1.36B
1.69B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.35B
1.78B
1.43B
1.91B
Operating expense
2.69B
3.34B
2.78B
3.60B
Total operating expenses
4.26B
4.96B
4.23B
5.18B
Operating income
3.51B
2.96B
2.73B
2.63B
Other non operating income
-23.00M
51.00M
-8.00M
-
EBT including unusual items
3.64B
2.08B
2.58B
-10.25B
EBT excluding unusual items
3.34B
2.80B
2.59B
2.42B
Income tax expense
589.00M
-105.00M
559.00M
242.00M
Effective tax rate
16.18%
-5.05%
21.67%
-2.36%
Other operating expenses
-
-
-
-
Net income
3.05B
2.18B
2.02B
-10.50B
Net profit margin
39.28%
27.55%
29.04%
-134.51%
Earnings per share
2.47
1.86
2.03
-6.75
Interest and investment income
88.00M
95.00M
95.00M
45.00M
Interest expense
-256.00M
-255.00M
-240.00M
-247.00M
Net interest expenses
-168.00M
-160.00M
-145.00M
-202.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.20B
3.65B
3.42B
3.33B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps